Patent applications published 11 May 2011
Selected patent applications from the weekly European Patents Bulletin
- Method for treating pulmonary diseases using rho kinase inhibitor compounds
Inspire Pharmaceuticals 2317849*
- Stigmine conjugates for substance use disorders
Colucid Pharmaceuticals 2317850*
- Pharmaceutical formulations containing dopamine receptor ligands
Forest Laboratories Holdings; Richter Gedeon Nyrt 2317852*
- Appetising medicaments for oral administration in solid form
Virbac 2317974*
- Appetising medicaments for oral administration in solid form for prevention and/or treatment of cardiac insufficiency in animals
Virbac 2317974*
- Octreotide implant having a release agent
Endo Pharmaceutical Solutions 2317975*
- Pharmaceutical compsn having relatively low ionic strength
Alcon Research 2317977*
- Stable injectable oil-in-water docetaxel nanoemulsion
Bharat Serums and Vaccines 2317978*
- Pharmaceutical compsns of somatotrophic hormones
Critical Pharmaceuticals 2317979*
- Pharmaceutical compsns of rivaroxaban with modified release properties
Ratiopharm 2317980*
- Multi-layered lamellar granule and skin external application compsns containing same
Amorepacific 2317981*
- Methods of processing compsns containing microparticles
Baxter International; Baxter Healthcare 2317982*
- Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
Laboratoires del Dr Esteve 2317983*
- Articles of manufacture releasing an active ingredient
Biomid Concepts 2317984*
- Modified release ramapril compsns and uses thereof
Panacea Biotec 2317985*
- System for the colon delivery of drugs subject to enzyme degradation and/or poorly absorbed in the gastrointestinal tract
Tavella, Gianaldo; Del Curto, Maria Dorly; Gazzaniga, Andrea; Maroni, Alessandra; Palugan, Luca; Zema, Lucia; Spreafico, Maddalena 2317986*
- Eprosartan compsns
Abbott Healthcare Products 2317987*
- Pharmaceutical dosage forms for time-specific drug delivery
Universita’ degli studia di Milano 2317989*
- Microparticulate oral drug form useful for the modified release form of nanoparticles
Flamel Technologies 2317990*
- Use of opioid antagonists for treating urinary retention
Euro-Celtique 2317991*
- Preventing or treating viral infection using an inhibitor of the LSD1 protein, a MAO inhibitor or an inhibitor of LSD1 and a MAO inhibitor
The United States of America, as represented by the Secretary, Department of Health and Human Services 2317992*
- Methods of administering topical antifungal formulations for the treatment of fungal infections
Tdt Ltd 2317993*
- Activation of histone deacetylase 1 (HDAC1) protests against DNA damage and increases neuronal survival
Massachusetts Institute of Technology 2317994*
- Inhibitors of MRP4 and agents stimulating MRP4 activity for the treatment of cardiac disorders
INSERM (Institut National de la Santé et de la Recherche Médicale) 2317995*
- Eltoprazine for suppression of L-DOPA induced dyskinesias
Björkland, Anders; Carta, Manolo; Lassen, Jørgen Buus 2317996*
- Low dose topiramate/phentermine compsn and methods for use thereof
Vivus 2317997*
- Fulvic acid and antibiotic combination
Pfeinsmith 2317998*
- Methods for modulating angiogenesis via dustrophin DP71
Institut National de la Sante et de la Recherche Medicale (INSERM) 2317999*
- Anti-tumoural effects of cannabinoid combinations
GW Pharma 2318000*
- Modified release formulation and methods of use
Valeant Pharmaceuticals International 2318001*
- Use of MTOR inhibitors to enhance T-cell immune responses
Emory University 2318002*
- Compsns for the treatment of fibrotic diseases or conditions
Kinemed 2318003*
- Pharmaceutical compsns containing a crystalline form of posaconazole
Sandoz 2318004*
- Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
Lixte Biotechnology 2318005*
- Novel pyrazole inhibitors of S-nitrosoglutathione reductase as therapeutic agents
N3O Pharmaceuticals 2318006*
- Novel pyrazole inhibitors of S-nitrosoglutathione reductase as therapeutic agents
N3O Pharmaceuticals 2318007*
- Binding and inhibiting 5-HT4 receptor
Immune Control 2318008*
- 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
Bayer Schering Pharma 2318009*
- Treating various disorders using TRKB agonists
Emory University 2318010*